dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse

This website has run out of funding so feel free to contribute if you can afford it (see footer)

Author Topic: How the Brain Judges Social Encounters  (Read 561 times)

Offline smfadmin (OP)

  • SMF (internal) Site
  • Administrator
  • Full Member
  • *****
  • Join Date: Dec 2014
  • Location: Management
  • Posts: 405
  • Reputation Power: 0
  • smfadmin has hidden their reputation power
  • Last Login:May 10, 2025, 07:02:27 AM
  • Supplied Install Member
How the Brain Judges Social Encounters
« on: May 02, 2025, 03:12:56 AM »
https://neurosciencenews.com/neuroscience-social-encounters-28790/

April 30, 2025

Summary:
Scientists have identified the neural circuitry responsible for assigning emotional value, positive or negative, to social encounters. Two key neuromodulators, serotonin and neurotensin, were found to control opposing emotional responses in a brain region responsible for learning and memory.

In a mouse model of autism spectrum disorder (ASD), activating serotonin receptors restored the ability to form positive impressions from social interactions. The findings could pave the way for therapies that target emotional imbalances in disorders like ASD and schizophrenia.

Key Facts:

● Emotional Tagging: Serotonin and neurotensin in the hippocampus determine whether a social interaction feels positive or negative.

● Reversing Deficits: Stimulating serotonin 1B receptors restored positive social impressions in a mouse model of ASD.

● Therapeutic Potential: The study reveals specific neuromodulatory targets that could inform future treatments for social cognitive deficits.

Mount Sinai researchers have identified for the first time the neural mechanisms in the brain that regulate both positive and negative impressions of a social encounter, as well as how an imbalance between the two could lead to common neuropsychiatric disorders like autism spectrum disorder (ASD) and schizophrenia.

The study, published April 30 in Nature, also describes how activating a serotonin receptor in the brain of a mouse model of ASD restored positive emotional value (also known as “valence”), with encouraging implications for the development of future therapies.

“The ability to recognize and distinguish unpleasant from pleasant interactions is essential for humans to navigate their social environment,” says Xiaoting Wu, PhD, Assistant Professor of Neuroscience at the Icahn School of Medicine at Mount Sinai, and senior author of the study.

“Until now, it has been unclear how the brain assigns positivity or negativity—‘valence’—to social experiences, and how that information can be flexibly updated in a constantly changing environment.”

At the center of this complex neural circuitry is the hippocampus, located deep in the temporal lobe of the brain and responsible for forming new memories, learning, and emotions.

The Mount Sinai researchers described how two neuromodulators—serotonin and neurotensin, which influence processes such as mood, arousal, and neural plasticity—are released into the hippocampal subregion known as ventral CA1, where they control opposing social valence assignment.

Both neurotransmitters impact distinct populations of ventral CA1 neurons through their respective receptors, serotonin 1B and neurotensin 1.

While deficits in social valence are known to be prevalent in many neuropsychiatric disorders, their underlying neural mechanisms and pathophysiology have remained elusive.

“Through our work we’ve provided the first foundational insights into the neural basis of social valence,” notes Dr. Wu.

“We have demonstrated that the neuromodulators serotonin and neurotensin signal opposing valence, revealing a fundamental principle of brain function in the form of a neuromodulatory switch that allows behavioral adaptation based on social history.”

Specifically, the team developed a novel social cognitive paradigm that involved exposing mice to negative and positive social encounters. In the negative social encounter, the test mouse was exposed to a mean/aggressive mouse; in the positive encounter, the mouse was exposed to a potential mate.

In both assays the mice had negative or neutral/positive or neutral interaction and then got to choose which mouse they would like to spend more time with.

Without prior experience, the mice did not have a preference, but with the experience, they associated a mouse with a positive or negative valence and then learned to avoid the “bad” mouse or approach the “good” mouse.”

Just as importantly, the team uncovered specific drug targets for positive and negative valence, knowledge that could potentially factor into future treatments.

Specifically, serotonin acting on the serotonin 1B receptor generates a positive impression of a social encounter, while neurotensin acting on the neurotensin 1 receptor creates a negative impression. Imbalanced emotional processing of those two social experiences is known to be a debilitating symptom of ASD.

Consequently, by activating the serotonin 1B receptor, researchers were able to restore a positive impression associated with rewarding social experiences.

“We identified a specific neuromodulator receptor which we then targeted to rescue social cognitive deficits in a mouse model of ASD,” Dr. Wu explains.

"On a broader scale, our work provides critical insights into complex social behaviors while revealing potential therapeutic targets that can be leveraged to improve social cognitive deficits in common neuropsychiatric disorders.”



While deficits in social valence are known to be prevalent in many neuropsychiatric disorders, their underlying neural mechanisms and pathophysiology have remained elusive. Credit: Neuroscience News
« Last Edit: May 02, 2025, 03:21:28 AM by smfadmin »
friendly
0
funny
0
informative
0
agree
0
disagree
0
like
0
dislike
0
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
measure twice, cut once

Tags:
 

Related Topics

  Subject / Started by Replies Last post
6 Replies
22510 Views
Last post July 03, 2016, 10:10:42 PM
by Chip
0 Replies
10537 Views
Last post September 26, 2017, 06:26:18 PM
by Chip
0 Replies
11119 Views
Last post May 18, 2018, 08:20:25 AM
by Chip
0 Replies
10307 Views
Last post July 02, 2019, 04:06:41 PM
by Chip
0 Replies
12212 Views
Last post October 22, 2019, 04:05:58 AM
by Chip
0 Replies
12791 Views
Last post March 13, 2020, 09:23:42 AM
by Chip
0 Replies
10289 Views
Last post May 30, 2021, 05:54:36 PM
by Chip
0 Replies
4133 Views
Last post November 16, 2024, 09:38:31 PM
by Chip
0 Replies
3200 Views
Last post December 14, 2024, 11:47:23 PM
by Chip
0 Replies
1319 Views
Last post April 08, 2025, 03:06:32 AM
by smfadmin


dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse





TERMS AND CONDITIONS

In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.


TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE


Founded December 2014
SimplePortal 2.3.6 © 2008-2014, SimplePortal